Global Cancer Angiogenesis Inhibitors Market & Clinical Pipeline Insight Report

“Global Cancer Angiogenesis Inhibitors Market & Clinical Pipeline Insight” Report Highlights:

* Angiogenesis Inhibitors: Introduction & Need in Cancer Therapy
* Modulators & Mechanism of Angiogenesis
* Classification of Angiogenesis Inhibitors
* Metronomic Therapy - A Recent Advancement in Anti-Angiogenesis Therapy
* Global Cancer Angiogenesis Inhibitors Clinical Pipeline by Company, Indication & Phase
* Global Cancer Angiogenesis Inhibitors Clinical Pipeline: 146 Drugs
* Marketed Cancer Angiogenesis Inhibitors Drugs: 11 Drugs

Download Report Sample Weblink:

https://www.kuickresearch.com/report-Global-Cancer-Angiogenesis-Inhibitors-Market-&-Clinical-Pipeline-Insight.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

1. Angiogenesis: History and Quest for Treatment



2. Angiogenesis Inhibitors: An Ounce of Cure & Prevention

2.1 Hallmarks of Cancer

2.1.1 Self Sufficiency in Growth Signals

2.1.2 Insensitivity to Antigrowth Signals

2.1.3 Acquired Capability: Evading Apoptosis

2.1.4 Limitless Replicative Potential

2.1.5 Sustained Angiogenesis

2.1.6 Tissue Invasion & Metastasis

2.2 Angiogenic- Metastatic Pathway as a Target for Anti-Cancer Therapies



3. What is Angiogenesis?

3.1 Stages of Angiogenesis

3.2 Types of Angiogenesis

3.2.1 Sprouting Angiogenesis

3.2.2 Intussusceptive Angiogenesis or Splitting Angiogenesis



4. Modulators of Angiogenesis

4.1 VEGF & Angiogenesis

4.2 Platelet Derived Growth Factor

4.3 Fibroblast Growth Factors (FGFs) & FGF Receptors

4.4 Endothelins & Endothelin Receptors

4.5 Erythropoietin & Erythropoietin Receptor

4.6 Angiopoietins & Tie2 Receptor



5. Mechanism of Angiogenesis

5.1 Dilation of Existing Vessels, Increase in Vascular Permeability & Degradation of Existing Vessels

5.2 Endothelial Cells Proliferation & Migration

5.3 Assembling of Endothelial Cells, Formation of Cords & Lumen

5.4 Long-Term Survival of Vascular Endothelium

5.5 Differentiation of Vascular Endothelium to Meet Local Needs



6. Classification of Angiogenesis Inhibitors

6.1 Direct Endogenous Inhibitors of Angiogenesis

6.2 Indirect Inhibitors of Angiogenesis

6.3 Conventional Chemotherapeutic Agents

6.4 VEGF Targeted Therapy

6.5 FGF Targeted Therapies

6.6 Oncogene Targeted Therapy

6.7 Matrix Degrading & Remodeling Targeted Therapy

6.8 Stromal Tumor Associated Cell Targeted Therapy

6.9 Cell Adhesion Molecules (CAMs) Targeted Therapy

6.10 Inflammatory Angiogenesis Targeted Therapy



7. Metronomic Therapy - A Recent Advancement in Anti-Angiogenesis Therapy



8. Applications of Angiogenesis Inhibitors

8.1 Quantitation & Prognosis of Malignant Disorders

8.2 Antiangiogenic Therapies

8.2.1 Cancer

8.2.2 Interferon Alpha-2α to Treat Hemangiomas

8.2.3 Ocular Neovascularization



9. Global Angiogenesis Inhibitors Market overview

9.1 Current Market Scenario

9.2 Global Cancer Angiogenesis Inhibitors Clinical Pipeline Overview



10. Global Cancer Angiogenesis Inhibitors Market Dynamics

10.1 Favorable Market Parameters

10.1.1 Large Global Patient Pool

10.1.2 Severity of the Disease

10.1.3 Side Effects of the Existing Drugs

10.1.4 Unmet Requirement of Completely Curative Agents

10.2 Major Challenges of Cancer Angiogenesis Inhibitors Market

10.2.1 Difficulties Associated with Evaluation of Anti Angiogenic Effect of Drugs

10.2.2 Prospects of Delayed Toxicity with Long-Term Anti-Angiogenic Therapy

10.2.3 Need of the Better Therapy Models

10.2.4 Approval from Regulatory Guidelines: A Major Challenge

10.2.5 Journey of Drug from Bench to Bedside: A Matter of Money & Time



11. Concluding Remarks & Future Market Prospects



12. Global Cancer Angiogenesis Inhibitors Clinical Pipeline by Company, Indication & Phase

12.1 Unknown

12.2 Research

12.3 Preclinical

12.4 Clinical

12.5 Phase-I

12.6 Phase-I/II

12.7 Phase-II

12.8 Phase-II/III

12.9 Phase-III

12.10 Preregistration



13. Marketed Cancer Angiogenesis Inhibitors Clinical Insight by Company & Indication

13.1 Apatinib

13.2 Lenalidomide (Ladevina & Revlimid)

13.3 Pomalidomide (Imnovid & Pomalyst)

13.4 Sorafenib (Nexavar)

13.5 Thalidomide (Thaled, Thalidomide Celgene & Thalomid)

13.6 Pazopanib (Votrient)

13.7 Bevacizumab (Avastin)

13.8 Bevacizumab Biosimilar (Cizumab)

13.9 Cetuximab (Erbitux)

13.10 Axitinib (Inlyta)

13.11 Recombinant Human Endostatin (Endostar & Endu)



14. Discontinued & Suspended Cancer Angiogenesis Inhibitors Clinical Pipeline by Company & Phase

14.1 No Development Reported

14.2 Discontinued

14.3 Suspended



15. Competitve Landscape

15.1 Advenchen Laboratories

15.2 Allergan

15.3 Alnylam Pharmaceuticals

15.4 Amgen

15.5 Angstrom Pharmaceuticals

15.6 Acceleron Pharma

15.7 Biocon

15.8 Bionomics

15.9 CASI Pharmaceuticals

15.10 Celgene Corporation

15.11 Enzon Pharmaceuticals

15.12 Five Prime Therapeutics

15.13 Fujifilm Kyowa Kirin Biologics

15.14 Genentech

15.15 Genexine

15.16 Hetero Drugs

15.17 ImClone Systems

15.18 Intas Pharmaceuticals

15.19 Kyowa Hakko Kirin

15.20 Levolta Pharmaceuticals

15.21 Mabtech

15.22 Marsala Biotech

15.23 Neumedicines

15.24 Novartis

15.25 Oncobiologics

15.26 Onyx Pharmaceuticals

15.27 Pfizer

15.28 Philogen

15.29 TBG Diagnostics

15.30 Reliance Life Sciences

15.31 Roche

15.32 Samsung Bioepis

15.33 Simcere Pharmaceutical

15.34 SynCore Biotechnology

15.35 TaiRx

15.36 Taiwan Liposome

15.37 Tiltan Pharma

15.38 XBiotech

Figure 3-1: Different Stages of Involved in Angiogenesis

Figure 3-2: Different Types of Angiogenesis

Figure 3-3: Steps Involved in Sprouting Angiogenesis

Figure 3-4: Steps Involved in Splitting Angiogenesis

Figure 4-1: Different Types of Modulators of Angiogenesis

Figure 4-2: Pathway Followed by VEGF during Angiogenesis

Figure 4-3: Modulatory Pathway of FGF in Angiogenesis

Figure 4-4: Basic Pathway Followed by Modulators to Facilitate Angiogenesis

Figure 5-1: Mechanism of Angiogenesis Stimulated by Tumor Cells

Figure 6-1: Various Categories of Angiogenesis Inhibitors

Figure 8-1: Important Applications of Angiogenic Inhibitors

Figure 9-1: Global Cancer Angiogenesis Inhibitors Clinical Pipeline by Phase (%), 2016

Figure 9-2: Global Cancer Angiogenesis Inhibitors Clinical Pipeline by Phase (Numbers), 2016

Figure 9-3: Global Cancer Angiogenesis Inhibitors Suspended & Discontinued in Clinical Pipeline (%), 2016

Figure 9-4: Global Cancer Angiogenesis Inhibitors Suspended & Discontinued in Clinical Pipeline (Numbers), 2016

Figure 10-1: Favorable Parameters for Cancer Angiogenesis Inhibitors Market

Figure 10-2: Major Challenges of Cancer Angiogenesis Inhibitors Market

Figure 15-1: Advenchen Laboratories - Clinical Pipeline

Figure 15-2: Alexion Pharmaceuticals - Clinical Pipeline

Figure 15-3: Alnylam Pharmaceuticals – Clinical Pipeline

Figure 15-4: Amgen - Clinical Pipeline

Figure 15-5: Acceleron Pharma – Clinical Pipeline

Figure 15-6: Biocon - Clinical Pipeline

Figure 15-7: Bionomics – Clinical Pipeline

Figure 15-8: Casi Pharmaceutical - Clinical Development

Figure 15-9: Celgene - Clinical Pipeline

Figure 15-10: Five Prime Therapeutics – Clinical Pipeline

Figure 15-11: Fujifilm Kyowa Kirin Biologics - Clinical Pipeline

Figure 15-12: Genexine - Clinical Pipeline

Figure 15-13: Levolta Pharmaceuticals – Clinical Pipeline

Figure 15-14: Neumedicines - Clinical Pipeline

Figure 15-15: Novartis - Clinical Pipeline

Figure 15-16: Oncobiologics - Clinical Pipeline

Figure 15-17: Philogen – Clinical Pipeline

Figure 15-18: Samsung Bioepis - Clinical Pipeline

Figure 15-19: Simcere Pharmaceutical Group – Clinical Pipeline

Figure 15-20: SynCore Biotechnology – Clinical Pipeline



Table 1-1: List of the Major Events in History of Angiogenesis Inhibitors Development

Table 2-1: List of FDA Approved Drugs & Their Target Cancer

Table 4-1: List of Some Angiogenesis Inhibitors & Their Target Receptors

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.